Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2015

Study Completion Date

January 31, 2016

Conditions
Anemia, Aplastic
Interventions
DRUG

Fludarabine

Doses of 30 mg/m\^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)

DRUG

Cyclophosphamide 150mg

A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)

DRUG

Cyclophosphamide 100mg

A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)

DRUG

Cyclophosphamide 50mg

A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2

Trial Locations (22)

10021

Memorial Sloan-Kettering Cancer Center, New York

14263

Roswell Park Cancer Institute, Buffalo

23298

Virginia Commonwealth University, MCV Hospital, Richmond

27705

Duke University Medical Center, Durham

30322

Children's Healthcare of Atlanta, Atlanta

30342

BMT Program at Northside Hospital, Atlanta

33624

H. Lee Moffitt Cancer Center, Tampa

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

48109

University of Michigan, Ann Arbor

55455

University of Minnesota, Minneapolis

76104

Cook Children's Medical Center, Fort Worth

77030

University of Texas, MD Anderson CRC, Houston

78229

Texas Transplant Institute, San Antonio

85016

Phoenix Children's Hospital, Phoenix

90027

Children's Hospital Los Angeles, Los Angeles

90095

Mattel Children's Hospital at UCLA, Los Angeles

91010

City of Hope National Medical Center, Duarte

94305

Stanford Hospital and Clinics, Stanford

98109

Fred Hutchinson Cancer Research Center, Seattle

02114

DFCI/Brigham & Women's Hospital, Boston

07601

Hackensack University Medical Center, Hackensack

97239-3098

Oregon Health & Science University, Portland

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Blood and Marrow Transplant Clinical Trials Network

NETWORK

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Marrow Donor Program

OTHER

lead

Medical College of Wisconsin

OTHER

NCT00326417 - Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) | Biotech Hunter | Biotech Hunter